136 related articles for article (PubMed ID: 22996376)
21. Biomarker expression and druggable gene alterations for development of an appropriate therapeutic protocol for pulmonary adenosquamous carcinoma.
Watanabe Y; Shiraishi K; Takahashi F; Yoshida A; Suzuki K; Asamura H; Takeuchi M; Furuta K; Tsuta K
Histopathology; 2015 Jun; 66(7):939-48. PubMed ID: 25257380
[TBL] [Abstract][Full Text] [Related]
22. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
[TBL] [Abstract][Full Text] [Related]
23. Large cell carcinoma of the lung: clinically oriented classification integrating immunohistochemistry and molecular biology.
Rossi G; Mengoli MC; Cavazza A; Nicoli D; Barbareschi M; Cantaloni C; Papotti M; Tironi A; Graziano P; Paci M; Stefani A; Migaldi M; Sartori G; Pelosi G
Virchows Arch; 2014 Jan; 464(1):61-8. PubMed ID: 24221342
[TBL] [Abstract][Full Text] [Related]
24. Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing.
Rekhtman N; Brandt SM; Sigel CS; Friedlander MA; Riely GJ; Travis WD; Zakowski MF; Moreira AL
J Thorac Oncol; 2011 Mar; 6(3):451-8. PubMed ID: 21266922
[TBL] [Abstract][Full Text] [Related]
25. KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma.
Rekhtman N; Ang DC; Riely GJ; Ladanyi M; Moreira AL
Mod Pathol; 2013 Oct; 26(10):1307-19. PubMed ID: 23619604
[TBL] [Abstract][Full Text] [Related]
26. Mutations of K-ras oncogene and absence of H-ras mutations in squamous cell carcinomas of the lung.
Vachtenheim J; Horáková I; Novotná H; Opáalka P; Roubková H
Clin Cancer Res; 1995 Mar; 1(3):359-65. PubMed ID: 9815992
[TBL] [Abstract][Full Text] [Related]
27. [Diagnosis of lung biopsy employing the 2015 WHO criteria and detection of related oncogenic driver mutations].
Fang F; Qiao XB; Yang L; Di J; Hu ST; Liu DG; Lyu N
Zhonghua Bing Li Xue Za Zhi; 2019 Apr; 48(4):270-275. PubMed ID: 30955261
[No Abstract] [Full Text] [Related]
28. Patients with ROS1 rearrangement-positive non-small-cell lung cancer benefit from pemetrexed-based chemotherapy.
Song Z; Su H; Zhang Y
Cancer Med; 2016 Oct; 5(10):2688-2693. PubMed ID: 27544536
[TBL] [Abstract][Full Text] [Related]
29. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations.
Rekhtman N; Paik PK; Arcila ME; Tafe LJ; Oxnard GR; Moreira AL; Travis WD; Zakowski MF; Kris MG; Ladanyi M
Clin Cancer Res; 2012 Feb; 18(4):1167-76. PubMed ID: 22228640
[TBL] [Abstract][Full Text] [Related]
30. Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed.
Camidge DR; Kono SA; Lu X; Okuyama S; Barón AE; Oton AB; Davies AM; Varella-Garcia M; Franklin W; Doebele RC
J Thorac Oncol; 2011 Apr; 6(4):774-80. PubMed ID: 21336183
[TBL] [Abstract][Full Text] [Related]
31. [The clinical and pathological features, biomarker characteristics and prognosis analysis of lung adenosquamous carcinoma].
Zhou SY; Xue Q; Ying JM; Hu XS; Yang JL; Lin H; Shi YK
Zhonghua Zhong Liu Za Zhi; 2019 Jan; 41(1):50-55. PubMed ID: 30678417
[No Abstract] [Full Text] [Related]
32. MUC1 and bcl-2 expression in preinvasive lesions and adenosquamous carcinoma of the lung.
Demirag F; Cakir E; Bayiz H; Eren Yazici U
Acta Chir Belg; 2013; 113(1):19-24. PubMed ID: 23550464
[TBL] [Abstract][Full Text] [Related]
33. The long-term survival of a patient with adenosquamous lung carcinoma harboring EGFR-activating mutations who was treated with gefitinib.
Iwanaga K; Sueoka-Aragane N; Nakamura T; Mori D; Kimura S
Intern Med; 2012; 51(19):2771-4. PubMed ID: 23037472
[TBL] [Abstract][Full Text] [Related]
34. BCL10 as a useful marker for pancreatic acinar cell carcinoma, especially using endoscopic ultrasound cytology specimens.
Hosoda W; Sasaki E; Murakami Y; Yamao K; Shimizu Y; Yatabe Y
Pathol Int; 2013 Mar; 63(3):176-82. PubMed ID: 23530562
[TBL] [Abstract][Full Text] [Related]
35. Molecular profiles of EGFR, K-ras, c-met, and FGFR in pulmonary pleomorphic carcinoma, a rare lung malignancy.
Lee S; Kim Y; Sun JM; Choi YL; Kim JG; Shim YM; Park YH; Ahn JS; Park K; Han JH; Ahn MJ
J Cancer Res Clin Oncol; 2011 Aug; 137(8):1203-11. PubMed ID: 21626008
[TBL] [Abstract][Full Text] [Related]
36. Use of epidermal growth factor receptor/Kirsten rat sarcoma 2 viral oncogene homolog mutation testing to define clonal relationships among multiple lung adenocarcinomas: comparison with clinical guidelines.
Girard N; Deshpande C; Azzoli CG; Rusch VW; Travis WD; Ladanyi M; Pao W
Chest; 2010 Jan; 137(1):46-52. PubMed ID: 19376842
[TBL] [Abstract][Full Text] [Related]
37. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.
Cai G; Wong R; Chhieng D; Levy GH; Gettinger SN; Herbst RS; Puchalski JT; Homer RJ; Hui P
Cancer Cytopathol; 2013 Sep; 121(9):500-7. PubMed ID: 23495083
[TBL] [Abstract][Full Text] [Related]
38. Assessment of cytology based molecular analysis to guide targeted therapy in advanced non-small-cell lung cancer.
Li W; Zhang Z; Guo L; Qiu T; Ling Y; Cao J; Guo H; Zhao H; Li L; Ying J
Oncotarget; 2016 Feb; 7(7):8332-40. PubMed ID: 26789109
[TBL] [Abstract][Full Text] [Related]
39. Low frequency of alterations in p53, K-ras, and mdm2 in rat lung neoplasms induced by diesel exhaust or carbon black.
Swafford DS; Nikula KJ; Mitchell CE; Belinsky SA
Carcinogenesis; 1995 May; 16(5):1215-21. PubMed ID: 7539340
[TBL] [Abstract][Full Text] [Related]
40. High-grade neuroendocrine carcinoma of the lung shows increased thymidylate synthase expression compared to other histotypes.
Ibe T; Shimizu K; Nakano T; Kakegawa S; Kamiyoshihara M; Nakajima T; Kaira K; Takeyoshi I
J Surg Oncol; 2010 Jul; 102(1):11-7. PubMed ID: 20578072
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]